Baxter Issues Urgent Medical Device Correction Regarding Potential Radio Frequency Interference With Other Devices Near Beds Installed With WatchCare System

Summary Company Announcement Date: October 21, 2022 FDA Publish Date: October 24, 2022 Product Type: Medical Devices Reason for Announcement: Recall Reason Description Potential for radio frequency (RF) interference with other medical devices. Company Name: Baxter International Inc. Brand Name: Brand Name(s) Product Description: Product Description Incontinence management system Company Announcement Baxter International Inc. announced…

Lo que debe saber sobre el riesgo de Cronobacter en la fórmula infantil en polvo

Image English La Administración de Alimentos y Medicamentos de EE. UU. continúa contribuyendo a garantizar la seguridad de la fórmula infantil en polvo a raíz de los informes de infecciones por Cronobacter sakazakii en cuatro bebés lo que pudo haber contribuido a la muerte de dos pacientes. Esos informes dieron lugar a una investigación de…

What to Know About the Risk of Cronobacter in Powdered Infant Formula

Image The U.S. Food and Drug Administration continues to help ensure the safety of powdered infant formula in the wake of reports of Cronobacter sakazakii infections in four infants that may have contributed to death in two patients. Those reports led to an FDA investigation of Abbott Nutrition in Sturgis, Michigan. Insanitary conditions found at…

FDA D.I.S.C.O. Burst Edition: FDA approval of Pedmark (sodium thiosulfate) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors

Podcast Welcome back to the D.I.S.C.O., FDA’s Drug Information Soundcast in Clinical Oncology, Burst Edition, brought to you by FDA’s Division of Drug Information in partnership with FDA’s Oncology Center of Excellence. Today we’ll provide a quick update on a recent FDA cancer drug approval. On September 20, 2022, the FDA approved sodium thiosulfate (brand…

FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer

Podcast Welcome back to the D.I.S.C.O., FDA’s Drug Information Soundcast in Clinical Oncology, Burst Edition, brought to you by FDA’s Division of Drug Information in partnership with FDA’s Oncology Center of Excellence. Today we’ll provide a quick update on a recent FDA cancer drug approval. On September 2, 2022, FDA approved durvalumab (brand name Imfinzi)…

Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL Vial, 20-Count Carton Due to Vial Breakage

Summary Company Announcement Date: October 12, 2022 FDA Publish Date: October 13, 2022 Product Type: Drugs Reason for Announcement: Recall Reason Description Vial Breakage Company Name: Exela Pharma Sciences, LLC Brand Name: Brand Name(s) Exela & Civica Product Description: Product Description Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial Company Announcement FOR IMMEDIATE RELEASE…

El fluorouracilo y la seguridad de las mascotas

Image CaptionFoto de cortesía English Para muchos hogares, las mascotas son nuestros mejores amigos. Para algunas personas son también animales de servicio indispensables. Muchos demuestran su afecto lamiéndonos. A otros les gusta morder cosas —los muebles, los zapatos, el bolso— cualquier cosa que esté a su alcance. Esto incluye los envases de cremas medicinales que…